QuVa Pharma in Training Program for First Responders in Terror Events
— Bloomsbury, NJ facility used for Special Operations “active shooter” exercise—
Sugar Land, TX – Mar 6, 2018 — QuVa Pharma, Inc. today announced that it has partnered with local law enforcement and special operations units to provide use of its Bloomsbury, New Jersey Facility to support the surrounding counties Special Operations First Responder Training for terror events. The initiative has been coordinated between the Office of the Prosecutor for Warren County, Office of the Hunterdon County Prosecutor’s Office, and QuVa Pharma. This course has been designed to improve the safety and survivability of victims of an active shooter in mass shooting situations, and increase the effectiveness, coordination, and resource integration between law enforcement, fire, and EMS when responding to these tragedies.
We are very pleased to be able to support our law enforcement agencies in this manner” said Stuart Hinchen, co-founder and Chief Executive Officer of QuVa Pharma. “Community involvement is integral to our company’s values and we were delighted this opportunity presented itself to aid law enforcement training.”
Mike Rutkowski, Vice President and General Manager of the Bloomsbury site commented. “QuVa Pharma’s foundation is based on training and planning and as such, we look to support our community to meet current and future needs to protect our most valuable assets; our people”.
“In Warren County, law enforcement regularly prepares for a variety of threats, with the hope that they will never occur. With the assistance of community partners like QuVa Pharma, we are able to provide our first responders with cutting edge training that will prepare them for any eventuality” commented Richard T. Burke, Prosecutor for the Warren County Prosecutor’s Office
Said Prosecutor Kearns, “The Hunterdon County Prosecutor’s Office is proud to partner with the Warren County Prosecutor’s Office and QuVa Pharma to provide this valuable training to our first responders. We must remain vigilant of potential threats and ensure our law enforcement, fire, and emergency medical services are prepared and provided with the training necessary to save lives. I am thankful to QuVa Pharma for their support and use of the Bloomsbury facility.”
QuVa Pharma acquired the 140-acre Bloomsbury facility in October 2016. Since commencing operations at the site in July 2017 more than 50 new skilled jobs have been created with the support of local colleges and leadership institutions. The Company expects over 100 more new positions to be added in the next twelve months as the operations expand. By the end of 2018, QuVa Pharma will have invested more than $30 million into the facility.
For inquiries please contact Peter Jenkins via email at: Peter.Jenkins@QuVaPharma.com
About QuVa Pharma, Inc.
QuVa Pharma is a nationally recognized company emerging as the leading industry 503B platform and partner of choice for compliance-oriented healthcare facilities looking to ensure a quality, safe and consistent supply of medications. The Company offers a broad portfolio of products across Pain Management, Anti-infective, OR Syringes, Labor and Delivery therapeutic areas amongst others, all of which are released only once sterility and potency testing is successfully complete, and with validation supporting appropriate BUD. The company is committed to having a patient-first orientation, as well as a robust product portfolio, leading safety standards, and collaborative, partnership-oriented customer service. For more information, visit www.quvapharma.com.